We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Identification of Outcome Predictors and Stratification of Responder Profiles Implanted With Spinal Cord Stimulation. An AI-based-pathway & Algorithmic Approach to Treat Failed Back Surgery Syndrome Patients (PREDIBACK 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04587674
Recruitment Status : Recruiting
First Posted : October 14, 2020
Last Update Posted : June 13, 2022
Sponsor:
Information provided by (Responsible Party):
Poitiers University Hospital

Tracking Information
First Submitted Date  ICMJE September 4, 2020
First Posted Date  ICMJE October 14, 2020
Last Update Posted Date June 13, 2022
Actual Study Start Date  ICMJE April 19, 2021
Estimated Primary Completion Date May 1, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 13, 2020)
Composite SCS efficacy score [ Time Frame: 6 months ]
Rate of SCS responders is defined as having at least three of these criteria:
  • Having at least a 30% decrease in Oswestry Disability Index (ODI) percentage. 10 items ranging from 0 to 5 where 0 indicates high ability and 5 indicate the inability.
  • Having at least a 50% decrease in the Visual Analogic Scale (VAS) (0 = no back pain, 10=worst imaginable pain)
  • Having at least a 0.2 points increase in the EuroQol-5 Dimensions (EQ-5D) questionnaire score. The maximum score of 1 indicates the best possible quality of life.
  • Having a decrease of 1.4 points in the Hospital Anxiety-Depression Scale (HADS) score. The total score ranges from 0 to 24 for each category.
  • 30% decrease pain surface (cm²): pain will assess painful area in terms of intensity, surface and pain typology.
  • Having a Patient Global Impression of Change (PGIC) score of at least 6. PGIC is a 7-point scale.
  • Drug intake will be measured using the Medication Quantification Scale (MQS) with a reduction of 3.4 points.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 13, 2020)
  • Pain intensity [ Time Frame: 6 months ]
    Pain intensity will be assessed using the Visual Analogic Scale (VAS score : 0 "no pain" to 10 "worst pain")
  • Pain surface [ Time Frame: 6 months ]
    Pain mapping criteria will be compared. Pain mapping criteria include: Global Pain Surface (cm²), Pain intensities associated with the surface measurements, Mechanical/neuropathic components of pain surfaces.
  • Functional capacity [ Time Frame: 6 months ]
    Functional capacity will be assessed using the Oswestry Disability Index (ODI, 0 "no disability" to 100% "complete disability")
  • Impact of Quality of life [ Time Frame: 6 months ]
    Quality of life will be assessed using the EuroQol Five Dimensions index (EQ5D, 0 "dead" to 1 "perfect health")
  • Psychological distress [ Time Frame: 6 months ]
    Psychological distress will be assessed using the Hospital Anxiety and Depression Scale (HADS, For each subscale the total score is at most 21. A score of ≥11 is considered a clinically significant disorder)
  • Social insecurity [ Time Frame: 6 months ]
    Social insecurity will be assessed using the EPICES questionnaire [0 = low risk of insecurity to 100 = high risk of insecurity]
  • Psychological resilience [ Time Frame: 6 months ]
    Psychological resilience will be assessed using the CD-RISC-10 (10-item Connor-Davidson Resilience Scale) questionnaire. [0 = low resilience to 40 = high resilience]
  • Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia [ Time Frame: 6 months ]
    % of Type of lead (Spinal Cord Stimulation Monocolumn vs Multicolumn Lead)
  • Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia [ Time Frame: 6 months ]
    Stimulation intensity (mA, milliAmper)
  • Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia [ Time Frame: 6 months ]
    Stimulation pulse width (µs, microsecond)
  • Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia [ Time Frame: 6 months ]
    Stimulation frequency (Hz, Hertz)
  • Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia [ Time Frame: 6 months ]
    % of Stimulation Waveform (Low Dose, High Dose, Both), Electrical parameters
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Duration of standing position given by both Intellis and GT9X,
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Duration of sitting position given by both Intellis and GT9X,
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Duration of lying position given by both Intellis and GT9X,
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Duration of mobile position (activity) given by both Intellis and GT9X,
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Number of steps given by GT9X,
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Sleep duration given by GT9X,
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Sleep efficacy given by GT9X,
  • Spinal Cord Stimulation efficacy using objective measurement tools [ Time Frame: 6 months ]
    Intellis/SnapshotTM platform to the ActiGraph GT9X. -Sleep onset latency given by GT9X,
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Identification of Outcome Predictors and Stratification of Responder Profiles Implanted With Spinal Cord Stimulation. An AI-based-pathway & Algorithmic Approach to Treat Failed Back Surgery Syndrome Patients
Official Title  ICMJE Identification of Outcome Predictors and Stratification of Responder Profiles Implanted With Spinal Cord Stimulation. An AI-based-pathway & Algorithmic Approach to Treat Failed Back Surgery Syndrome Patients
Brief Summary

Failed Back Surgery Syndrome is commonly defined as new, recurrent, or persistent pain in the back and/or leg(s) of at least 6-month duration following spinal surgery. The literature estimates that 10-50% of patients undergoing spinal surgery are likely to develop such pain, representing a substantial financial burden. Among them, 5-10% would suffer from severe pain, which are intense, neuropathic and generally refractory to conventional therapeutic strategies considerably affect patients' functional capacity as well as their psychological and social well-being.

Spinal Cord Stimulation (SCS) is a well-established therapy to alleviate severe intractable neuropathic pain such as FBSS. SCS is a safe and reversible treatment option, which leads to improvement in pain relief and quality of life for patients with FBSS. Despite encouraging results in a chronic painful patient population that is refractory to conventional therapies, the literature estimates that only 58% [53% - 64%] of patients implanted with SCS devices achieved adequate pain relief.

FBSS population characterization and stratification and predictive modeling of SCS outcome are thus crucial to delineate future treatment options and to deliver neuromodulation therapy to the right patient.

The investigators designed a clinical prospective project based on SCS outcome optimization and SCS candidates' stratification: PREDIBACK 2.

This study would be a following part of a continuous project (PREDIBACK) that aims to better understand and stratify the therapies (drugs, surgery, psychological therapy or SCS) proposed to FBSS patients. The goal of PREDIBACK 1 was to develop a decision tool that simplifies the therapeutic decision process.

PREDIBACK 2 will focus on the neuromodulation pathway. Easing and helping patient orientation should improve referral yielding to specialists and accelerate patient flow through care pathway. Hence, facilitating access to adequate therapies for FBSS patients who usually have a longstanding history of pain.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Condition  ICMJE Pain, Intractable
Intervention  ICMJE Device: Spinal Cord Stimulation
Lead(s) and Implant Pulse Generator
Study Arms  ICMJE Spinal Cord Stimulation
Intervention: Device: Spinal Cord Stimulation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 13, 2020)
110
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2023
Estimated Primary Completion Date May 1, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Selection Criteria:

  • Subject is ≥ 18 years and ≤ 80 years.
  • Subject has FBSS and does not require further surgery. For the purpose of this study, FBSS is defined as persistent or recurrent low back and leg pain of at least 6-month duration following at least one decompression and/or fusion procedure.
  • Subject has persistent low back and leg pain despite other treatment modalities (pharmacological, surgical, physical, or psychological therapies) that have been tried and did not prove satisfactory or are unsuitable or contraindicated for the subject.
  • VAS global pain is ≥ 50 mm.
  • Subject meets the criteria for spinal cord stimulation test according to HAS guidelines (multidisciplinary consultation, psychological assessment...).
  • Absence of active psychosis or history of serious psychotic illness requiring hospitalization.
  • Subject understands and accepts the constraints of the study.
  • Patient covered by French national health insurance.
  • Patient who has given written consent to the study after having received clear information.

Non-inclusion Criteria:

  • Subject is or has been treated with SCS, subcutaneous or peripheral nerve stimulation, an intrathecal drug delivery system, requires back surgery at the localization related to his/her original back pain complaint or experimental therapies.
  • Subject low back pain is coming from a non-FBSS etiology (i.e. cancerous pain, infectious disease, etc.).
  • Cause of low back pain accessible to etiological "mechanical" surgical treatment (discogenic low back pain, vertebral instability, spinal deformity, etc.).
  • Subject had most recent back surgery less than 6 months ago.
  • Simultaneous participation to any interventional study during the study
  • Subject requiring closer protection, i.e. minors, pregnant women, nursing mothers, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patient in an emergency setting.

    • MRI contraindications if MRI is not available within a time frame of 2 years from the last spinal surgery. Absolute contraindications are: Cardiac implantable electronic device, metallic intraocular foreign bodies, cochlear implants, drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid, piercing
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Manul ROULAUD, MSc +33 5 49 44 32 23 manuel.roulaud@chu-poitiers.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04587674
Other Study ID Numbers  ICMJE 2020-A01734-35
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Poitiers University Hospital
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Poitiers University Hospital
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Philippe RIGOARD, MD, PhD Poitiers Hospital Unoversity
PRS Account Poitiers University Hospital
Verification Date June 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP